文献速递消化道肿瘤放疗放疗物理与技术

[18F]AlF-NOTA-FAPI-04 PET/CT可预测局部晚期直肠癌新辅助放化疗后病理完全缓解

[18F] AlF-NOTA-FAPI-04 PET/CT scans can predict pathologic complete response in patients receiving neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
PubMed 文献 · Radiother Oncol · 2026-02-05

该前瞻性研究纳入60例原发直肠癌患者,其中40例接受新辅助放化疗,评估[18F]AlF-NOTA-FAPI-04 PET/CT摄取参数对病理完全缓解(pCR)的预测价值。结果显示基线SUVmean和SUVmax均能预测pCR,SUVmean为独立预测因子,且摄取参数与CAF相关标志物表达正相关。

要点

  • 基线SUVmean可预测pCR,AUC=0.869,截断值6.02,灵敏度100%,特异度74.2%。
  • SUVmean是多因素分析中良好反应的独立预测因子(OR=0.295,95%CI 0.113-0.772,P=0.013)。
  • FAPI摄取参数与FAP表达正相关(p<0.05),第10次放疗后摄取变化与放疗反应无关。

核心结论

  • [18F]AlF-NOTA-FAPI-04 PET/CT摄取参数反映CAF相关标志物表达,基线高SUVmean与LARC新辅助放化疗反应差相关。

研究设计与样本

  • 前瞻性评估60例组织病理学确诊的原发直肠癌患者,其中20例转诊手术、40例接受nCRT。
  • 40例nCRT患者中26例在第10次放疗分次后接受第二次[18F]AlF-NOTA-FAPI-04 PET/CT以评估FAPI摄取变量变化。
  • 采用Spearman秩检验评估基线PET变量与CAF标志物的相关性,采用logistic回归评估病理缓解与潜在预测因素的关系。

主要发现

  • FAPI PET变量SUVmax和SUVmean与FAP表达正相关(p<0.05)。
  • ROC曲线分析显示原发肿瘤SUVmean预测pCR的AUC=0.869(p<0.001),截断值6.02,灵敏度100%,特异度74.2%。
  • 原发肿瘤SUVmax预测pCR的AUC=0.810(p=0.005),截断值11.46,灵敏度77.8%,特异度80.6%。
  • 多因素logistic回归显示SUVmean是良好反应的独立预测因子(OR=0.295,95%CI 0.113-0.772,p=0.013)。
  • FAPI摄取变量变化与放疗反应无相关性。

关键数值与推荐

  • SUVmean预测pCR:AUC=0.869,p<0.001,截断值6.02,灵敏度100%,特异度74.2%(原发肿瘤)。
  • SUVmax预测pCR:AUC=0.810,p=0.005,截断值11.46,灵敏度77.8%,特异度80.6%(原发肿瘤)。
  • SUVmean独立预测良好反应:OR=0.295,95%CI 0.113-0.772,p=0.013。

临床怎么用

  • 基线[18F]AlF-NOTA-FAPI-04 PET/CT的SUVmean可用于LARC新辅助放化疗前预测pCR,辅助筛选可能获益患者。
  • SUVmean截断值6.02对应灵敏度100%、特异度74.2%,高SUVmean提示反应差,可考虑更密切监测或治疗调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: We evaluated whether using the tracer [18F] AlF-NOTA-FAPI-04. in positron emission tomography/computed tomography (PET/CT) could predict pathologic complete response (pCR) rates in patients receiving neoadjuvant chemoradiotherapy (nCRT) for locally advanced rectal cancer (LARC). MATERIALS AND METHODS: We prospectively evaluated 60 patients with histopathologically confirmed primary rectal cancer (20 referred for surgery and 40 for nCRT) who provided pretreatment [18F] AlF-NOTA-FAPI-04 PET/CT scans to detect FAP on tumor surfaces. Among those 40 patients, 26 provided a second [18F] AlF-NOTA-FAPI-04 PET/CT scan after the 10th radiotherapy fraction to assess changes in FAPI uptake variables. Correlations between baseline PET variables and markers of cancer-associated fibroblasts (CAFs) were assessed with Spearman's rank test. Relationships between pathologic remission and potential predictors were assessed with logistic regression. RESULTS: The FAPI PET variables maximum and mean standardized uptake values (SUVmax, SUVmean) were positive correlated with FAP expression (p < 0.05). Receiver operating characteristic curve analysis identified SUVmean (area under the curve [AUC] = 0.869, p < 0.001; cutoff value 6.02; sensitivity 100%; specificity 74.2%) and SUVmax (AUC = 0.810, p = 0.005; cutoff value 11.46; sensitivity 77.8%; specificity 80.6%), both for the primary tumor, as predicting pCR. Multivariate logistic regression showed that SUVmean was an independent predictor of good response (odds ratio = 0.295, 95% confidence interval [CI] 0.113-0.772, p = 0.013). Changes in FAPI uptake variables were not correlated with radiotherapy response. CONCLUSIONS: [18F] AlF-NOTA-FAPI-04 PET/CT uptake variables reflected the expression of CAF-related biomarkers. Higher baseline SUVmean on [18F] AlF-NOTA-FAPI-04 PET/CT scans was associated with poor response to nCRT for LARC.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Zhu Z, Zhang X, Yun Z, et al. [18F] AlF-NOTA-FAPI-04 PET/CT scans can predict pathologic complete response in patients receiving neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Radiother Oncol. 2026. PMID: 41654222. doi:10.1016/j.radonc.2026.111429

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。